Trial Results Spark: Social media discussions center on Humacyte's Phase 3 trial outcomes for its vascular technology, which have driven notable stock gains. Observers point to accelerated buying as a key factor behind the recent upward movement.
Insider Moves Noted: Participants highlight an insider acquisition of shares alongside sales by a significant holder under a trading plan. These developments have prompted varied commentary on the company's trajectory.
Resilient Performance: Traders remark on the stock's unexpected strength in recent sessions amid broader biotech interest. The overall tone reflects cautious optimism tied to the trial advancements.
Note: This discussion summary was generated from an AI condensation of post data.
Humacyte Insider Trading Activity
Humacyte insiders have traded $HUMA stock on the open market 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- KATHLEEN SEBELIUS purchased 56,818 shares for an estimated $49,999
- DALE A. SANDER (CFO and Chief Corp. Dev. Off) sold 45,887 shares for an estimated $41,146
- SHAMIK J PARIKH (Chief Medical Officer) sold 45,887 shares for an estimated $41,146
- KEITH ANTHONY JONES purchased 30,000 shares for an estimated $17,820
- MICHAEL T. CONSTANTINO purchased 11,000 shares for an estimated $9,839
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Humacyte Hedge Fund Activity
We have seen 93 institutional investors add shares of Humacyte stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 7,477,026 shares (-60.7%) from their portfolio in Q2 2026, for an estimated $5,835,071
- ALYESKA INVESTMENT GROUP, L.P. added 6,022,925 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,700,290
- ANTIPODES PARTNERS LTD added 4,379,897 shares (+76.5%) to their portfolio in Q2 2026, for an estimated $3,418,071
- GREAT POINT PARTNERS LLC added 3,750,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,926,500
- STATE STREET CORP removed 2,201,392 shares (-72.3%) from their portfolio in Q2 2026, for an estimated $1,717,966
- MILLENNIUM MANAGEMENT LLC added 1,800,895 shares (+1665.1%) to their portfolio in Q2 2026, for an estimated $1,405,418
- WOODLINE PARTNERS LP removed 1,502,000 shares (-75.0%) from their portfolio in Q2 2026, for an estimated $1,172,160
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Humacyte Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 7 analysts offer price targets for $HUMA in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Joshua Jennings from TD Cowen set a target price of $1.25 on 06/17/2026
- Ryan Zimmerman from BTIG set a target price of $2.0 on 06/16/2026
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $4.0 on 06/11/2026
- Bruce D. Jackson from Benchmark set a target price of $2.0 on 06/01/2026
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 04/28/2026
- Matt Miksic from Barclays set a target price of $1.5 on 04/08/2026
- Allison Bratzel from Piper Sandler set a target price of $1.0 on 03/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
